Healius (ASX:HLS) has agreed to sell wholly owned subsidiary Agilex Biolabs to Novotech for an enterprise value of A$160 million, with approximately A$155 million expected in net cash proceeds after separation and transaction costs.

🧬 A$160m sale agreed: The transaction values Agilex Biolabs at 19.8x FY26 EBITDA on a pre-AASB16 basis, with completion expected during the second half of Healius’ FY27, subject to conditions including FIRB and ACCC approval.
💰 Healius moves to net cash: The transaction is expected to deliver approximately A$155 million in cash proceeds, with Healius not expecting to incur tax on the sale. On completion, the company expects to be in a net cash position and will assess its capital requirements and use of proceeds closer to completion.
🏥 Focus returns to pathology: Agilex Biolabs operates as a standalone business, meaning the sale will not impact Healius’ Pathology operations. Management says the disposal will support greater focus on growing and improving its core pathology business, which provides diagnostic services across Australia.

“The sale provides customers and team members of Agilex Biolabs with the opportunity to join an established and global business in Novotech, which has expertise in providing services to major biotechnology and pharmaceutical customers.” – Paul Anderson, Managing Director & CEO

Why US Pentagon wants Sunrise`s scandium ⛏️

How can a mining company skyrocket in value without mining anything yet? That`s what is happening to Sunrise Energy Metals (ASX:SRL), which wants to mine scandium in central New South Wales. Its stock is up over 400% in a year.

Scandium is a metal you`ve probably never heard of. It makes aluminium lighter and stronger, and it goes into fuel cells that could power AI data centres. The whole world uses only a few dozen tonnes a year, and China makes more than 85 per cent of it.

The US Department of War offered up to $400 million to build Sunrise`s mine, and got first dibs on what comes out. Lockheed Martin took an option on a quarter of early production. That`s the thing about a story stock. The loan is conditional, the Lockheed deal is an option, and the mine isn`t built. But the market loves the future, and right now it`s betting that Sunrise keeps rising.

#mining #scandium #US #stocks #AI

Matsa Resources (ASX:MAT) received a $10 million deposit from AngloGold Ashanti following the early exercise of an option to acquire specific tenements within the Lake Carey Gold Project near Laverton, Western Australia.

💰 $10m deposit received: The payment follows the revised Tenement Option Agreement announced on 22 September 2026, under which AngloGold Ashanti agreed to acquire selected Lake Carey tenements for $55 million.
⛏️ Completion conditions progress: Matsa Resources has received ministerial consent, satisfying a significant condition precedent. A limited number of further conditions remain, including third-party consents for the assignment of contractual access rights linked to the sale assets.
📈 $45m still payable: The remaining $45 million is due at completion, scheduled for 15 business days after the final completion conditions are satisfied. Matsa Resources says it will update shareholders when the final payment is received. At that time, the company will also provide some guidance on where the proceeds of the sale will be directed.

Rick Rule is speaking at IMARC this October, sharing his outlook on the resource cycle and where he sees opportunities across gold, copper, oil, gas and uranium. Rick tells The Stock Network`s Lel Smits that gold remains a savings asset in the middle of a long bull market, copper faces a supply shortfall that will be "rationed by price" and years of underinvestment have set up a structural deficit in oil and gas.

TSN Interview:
🪙 Why gold weakness is a gift
🪓 Copper will be rationed by price
🛢️ Oil, gas and uranium and the energy opportunity
⚒️ What Rick Rule looks for in a mining stock

Register for IMARC:
🗓 27 - 29 Oct 2026
📍 ICC Sydney
⚡ Promo code "tsn15"
👉 https://imarcglobal.com/register

4DMedical (ASX:4DX) Co-Founder and CEO, Andreas Fouras has presented at The Stock Network`s ASX Gems Investment Conference: AI Spotlight.

Myer sales and rate rise pain 🛍️

Want to see how interest rates affect the economy? Take a look at Myer (ASX:MYR). It just reported its results, and named the causes for a tough year: rate rises, higher fuel prices, slower income growth and a weaker housing market. Here`s the chain. Rates go up, so your repayments go up. That money has to come from somewhere, and it usually comes from the stuff you want rather than the stuff you need. Myer discounted harder to get people through the door, which means it sold roughly the same amount of stuff for less profit. Markets are betting that the RBA hikes again next week. Myer has already shown us what that will look like.

#myer #shopping #fintok #housing #money

HeraMED (ASX:HMD) CEO and Managing Director, Anoushka Gungadin has presented at The Stock Network`s ASX Gems Investment Conference: AI Spotlight.

Pengana Private Equity Trust (ASX:PE1) Investment Specialist, Will Dougall has presented at The Stock Network`s ASX Gems Investment Conference: AI Spotlight.